Administration of LMP1- and LMP2-specific cytotoxic T-lymphocytes to patients with EBV-positive nasopharyngeal carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs LMP1-LMP2-specific T lymphocyte therapy (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Acronyms NATELLA
- 07 Feb 2017 Biomarkers information updated
- 13 Apr 2012 Actual patient number is 29 according to ClinicalTrials.gov.
- 13 Apr 2012 Actual patient number is 29 according to ClinicalTrials.gov.